In Silico Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
Open Access
- 10 June 2025
- journal article
- review article
- Published by MDPI AG in Applied Sciences
- Vol. 15 (12) , 6544
Abstract
Coronaviruses (CoVs) have recently emerged as significant causes of respiratory disease outbreaks, with the novel coronavirus pneumonia of 2019, known as COVID-19, being highly infectious and triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Understanding virus–host interactions and molecular targets in host cell death signalling is crucial for inhibitor development. Among the promising targets for inhibitor development is the main protease (Mpro), which is essential for viral replication. While current research has focused mainly on covalent inhibitors, growing attention is being given to non-covalent inhibitors due to their potential for lower toxicity and improved resistance to viral mutations. This literature review provides an in-depth analysis of recent in silico approaches used to identify and optimise non-covalent inhibitors of SARS-CoV-2 Mpro. It focuses on molecular docking and robust molecular dynamics (MD) simulation technologies to discover novel scaffolds with better binding affinities. The article summarises recent studies that pre-screened several potential non-covalent inhibitors, including natural constituents like alkaloids, flavonoids, terpenoids, diarylheptanoids, and anthraquinones, using in silico methods. The in silico approach, pivotal to developing small molecules of Mpro non-covalent inhibitors, provides an efficient avenue to guide future research efforts toward developing high-performance Mpro inhibitors for SARS-CoV-2 Mpro, representing the latest advancements in drug design.Keywords
All Related Versions
This publication has 98 references indexed in Scilit:
- Improved fluorescence‐based assay for rapid screening and evaluation of SARS‐CoV‐2 main protease inhibitorsJournal of Medical Virology, 2024
- Structural Landscape of nsp Coding Genomic Regions of SARS-CoV-2-ssRNA Genome: A Structural Genomics Approach Toward Identification of Druggable Genome, Ligand-Binding Pockets, and Structure-Based DruggabilityMolecular Biotechnology, 2022
- The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19Medcomm, 2022
- Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS-CoV-2 Replication by Targeting Mpro and Sepsis in MiceInflammation, 2021
- Identification of novel inhibitors of SARS‐CoV‐2 main protease (Mpro) from Withania sp. by molecular docking and molecular dynamics simulationJournal of Computational Chemistry, 2021
- Accelerating optical reporting for conformation of tyrosine kinase inhibitors in solutionsInternational Journal of Quantum Chemistry, 2021
- Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)Molecular Biotechnology, 2021
- First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discoveryMolecular Diversity, 2021
- Quantum Mechanics in Drug Discovery2020
- Accurate magnetizabilities of the isoelectronic series BeH−, BH, and CH+. The MCSCF-GIAO approachChemical Physics, 1995